# Merit Medical Systems (MMSI) Stock Analysis: Exploring a 17.48% Upside Potential

- Link: https://www.directorstalkinterviews.com/merit-medical-systems-mmsi-stock-analysis-exploring-a-17-48-upside-potential/4121262437
- Published: 2026-09-14T10:21:23+01:00
- Author: Madison Wilson

Merit Medical Systems, Inc. (NASDAQ: MMSI) stands as a compelling player in the 
healthcare sector, specifically within the medical instruments and supplies industry.
Headquartered in South Jordan, Utah, the company has carved a niche in designing,
manufacturing, and marketing single-use medical products for a variety of procedures
across the globe. With a market capitalization of $5.16 billion, Merit Medical continues
to draw investor attention, especially with the potential upside of 17.48% indicated
by analyst ratings.

The current share price of $86.36 sits within a 52-week range of $60.31 to $93.18,
suggesting a stable growth trajectory. Despite a minor price change of -0.11 or 
0.00%, the stock has maintained its position close to the higher end of its annual
range. This stability is further underscored by technical indicators, such as the
50-day moving average of $83.20 and the 200-day moving average of $76.66, which 
indicate consistent upward momentum.

Analyst sentiment is notably positive with nine buy ratings, two holds, and zero
sell recommendations. The average target price of $101.45 offers a promising upside
from current levels, reflecting strong confidence in the company’s future performance.
Such optimism is bolstered by Merit Medical’s robust revenue growth of 9.50% and
an EPS of 2.43, which demonstrate the company’s ability to generate substantial 
earnings.

The lack of a trailing P/E ratio suggests that investors are focusing more on future
earnings potential, as evidenced by a forward P/E of 18.73. This forward-looking
valuation metric implies that the market expects continued growth and profitability.
Additionally, the company’s free cash flow of approximately $173.9 million highlights
its ability to reinvest in business operations, drive innovation, and potentially
support future growth initiatives.

While Merit Medical does not currently offer a dividend yield, its 0.00% payout 
ratio indicates that the company might be reinvesting earnings back into the business
to fuel expansion and development. This approach aligns with its comprehensive product
offerings, which cater to segments like cardiovascular and endoscopy, as well as
its broad international reach spanning North America, Europe, and Asia.

Technically, the stock’s RSI (14) of 55.14 suggests that it is neither overbought
nor oversold, providing a neutral stance for potential investors. The MACD of 0.85,
against a signal line of 1.90, also supports the neutral to positive sentiment, 
indicating that momentum may be gradually building in favor of the bulls.

Merit Medical’s extensive product portfolio, which includes cardiology, oncology,
and gastroenterology products, among others, positions it well in a healthcare sector
that is continually evolving and expanding. The company’s strategic partnerships
and distribution networks further enhance its market penetration and growth prospects.

As investors contemplate the potential of Merit Medical Systems, the combination
of strong analyst ratings, promising valuation metrics, and a diversified product
range presents a compelling case for those seeking exposure in the healthcare industry.
With a calculated focus on driving revenue growth and maintaining financial health,
MMSI remains a stock to watch for potential gains in the near to medium term.

Share on:
